Notice of Capital Markets Event

Venture Life Group PLC
09 May 2023

9 May 2023



("Venture Life", "VLG" or the "Company")


Notice of Capital Markets Event


Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that it will host a capital markets event for analysts and investors on 6 June 2023.

The event will be held at the offices of Simmons & Simmons LLP, 1 Ropemaker Street, London EC26 9SS, and senior executives and operational management will be presenting on the following:

·    The Venture Life key brands, being Balance Activ, Lift and Earol;


·    UK and international distribution, and how products are sold via each channel;


·    The Company's development and manufacturing capabilities;


·    Managing supply chains in the current environment; and


·    The Customer Brands that the Company manufactures.


The event will start at 14:00 GMT and is expected to finish at 17:00 GMT.

If you wish to attend the event in person, please RSVP to or

The Company invites retail investors to attend in person; however, there will be a limit to the number that can attend, and places will be given on a first come first serve basis.


For further information, please contact:

Venture Life Group PLC                                                                                          +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer


Cenkos Securities plc (Nomad and Joint Broker)                                                  +44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)


Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong  (Corporate Finance)                                            +44 (0) 20 74963000

Jonathan Dighe (Sales)


About Venture Life (

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings